MEC is a Wisconsin-based contract metal fabricator — sheet steel, aluminum extrusion, welding — serving OEM manufacturers across commercial vehicles, agriculture, powersports, and construction. In July 2025 they acquired Accu-Fab for $140.5M, bolting on data center and critical power fabrication at nearly double legacy margins. The stock has pulled back 11% in the last month, RSI 31.7, all five analysts say Buy with $23-$34.50 targets. The thesis is sector misclassification: market prices a cyclical OEM fabricator at trough, but the Accu-Fab acquisition is transforming the business into a DC infrastructure play.

The thesis is real. The price is wrong.

What the 10-K Shows

Six independent factors drive the MEC outcome. Only two are idiosyncratic. The rest are sector beta, macro, or gate variables you can't hedge.

Factor 1: Data Center Fabrication Demand. Accu-Fab contributed $40.7M revenue and $7.3M operating income in just H2 2025 — an $81M annualized run rate at 17.9% operating margin vs legacy MEC's 9.9%. Full-year DC revenue was $52.1M, up 198% YoY. This is the idiosyncratic driver and it's cross-ticker corroborated: AAON's DC sales up 143%, SPXC committing $100M to DC capacity, EME's DC electrical construction up 80%, Munters posting a 7.0x DC book-to-bill extending through 2028. No deceleration signal anywhere in the supply chain. If DC demand holds, EBITDA recovers and leverage falls naturally.

Factor 2: OEM Cyclical Recovery. Four of six legacy end markets declined 13-25% in FY2025. Commercial vehicle down 19%, agriculture down 25%, powersports down 14%, construction down 13%. Organic revenue ex-Accu-Fab was approximately $506M, down 13% YoY. PACCAR (13.6% of sales) and John Deere (10.0%) are the top two customers — both deep in cyclical trough. Consensus expects H2 2026 recovery, but management's own language is "inconsistent customer demand." No edge on OEM cycle timing. Pure sector beta.

Factor 3: Leverage Survival — The Gate. This is where the thesis lives or dies. Three credit amendments in less than 12 months — the 8th, 9th, and 10th amendments to the Wells Fargo revolving facility. The latest, filed February 25, 2026, seven days before the 10-K:

• Revolver capacity reduced from $350M to $275M
• Leverage covenant raised to 5.25x for Q1-Q2 2026 (from 4.00x)
• Interest coverage floor reduced from 3.00x to 2.75x through Q4 2026
• Additional interest rate tiers at higher leverage levels

At December 31, 2025, MEC had $202.5M drawn on the revolver, $1.5M cash, and $17.7M of availability. Total liquidity: $19M on a $546M revenue company. Single credit facility. No backup. No term loan. No ABL. Maturing June 2028.

Why request 5.25x headroom when actual leverage is 3.68x? Because management is projecting EBITDA deterioration in H1 2026. That's 43% headroom — they didn't ask for that to be cautious.

Two more details the bull case overlooks. First, the credit agreement explicitly prohibits sale-leaseback transactions. MEC owns 14 of 27 facilities, $150M of net PP&E — classic SLB setup — but the escape hatch is contractually sealed. The one facility held for sale (Wautoma, WI) carries $1.4M of book value. Negligible. Second, tangible book value is negative. Goodwill ($140M) and intangibles ($111M) from the Accu-Fab acquisition total $251M against $241M of shareholders' equity. If EBITDA doesn't recover to support the purchase price, the goodwill impairment test fails and equity gets written down. Deloitte flagged goodwill as a critical audit matter.

Factor 4: Management. The CFO, Rachele Lehr, was promoted directly from Chief Human Resources Officer (March 2023) to CFO (April 2025). No disclosed finance or accounting background. She was navigating $140.5M in leveraged acquisition financing and Wells Fargo covenant negotiations within five months of taking the role. PSU performance targets were missed — $2.634M of compensation reversed in FY2025 vs zero reversals in 2024. The board approved $960K in acquisition bonuses on March 2, 2026 — two days before the 10-K disclosed the covenant relief.

On the other hand: CEO Reddy bought $105K of stock in August at $14.06. CFO Lehr bought $19.7K at $14.08. Both post-Accu-Fab, both knowing the leverage picture. The people running the business bought. The people who aren't — General Counsel Leuba sold 9,198 shares ($176K) on March 5, one day after the 10-K filed — sold.

What the Market Prices

At $18.84, the market implies a forward P/E of 14.78. On 20.3M shares, that means approximately $26M of net income — a full turnaround from the $8.1M net loss in FY2025. Working backward through interest ($12M), taxes, and D&A ($41M), the implied forward EBITDA is approximately $85M. That's nearly double the $47M trailing Adjusted EBITDA.

To get $85M, everything has to work simultaneously: Accu-Fab annualization adds $20M, legacy margin recovery from 9.9% to 12.2% adds $11M, legacy volume recovery adds $4M, operating leverage adds $5M. All during tariff uncertainty, with management describing "inconsistent customer demand."

Enterprise value is $585M ($383M market cap + $202M net debt). On trailing Adj EBITDA, that's 12.4x — very expensive for a contract fabricator. On the street's forward $85M, it's 6.9x — a discount multiple for the leverage risk. Classic sell-side construction: optimistic earnings plus discount multiple equals a target that looks achievable.

Back-solving the market's implied probability distribution against my scenarios: the market is pricing approximately 54% bull, 31% base, and 15% bear. My estimate is 25% bull, 45% base, 30% bear. The disagreement centers on the bear case. Three covenant amendments, $19M liquidity, and negative tangible book — 30% bear is more defensible than 15%.

The Math

Three scenarios, 12-month horizon:

Bull (25%): DC demand accelerates, OEM recovers H2 2026, leverage peaks below 5.0x. EBITDA recovers to $80M, net debt pays down to $175M. At 8.5x (premium for DC growth mix), EV $680M, equity $505M, stock $24.88.

Base (45%): DC holds at run rate, OEM flat, leverage elevated but manageable at 4.0-4.5x. EBITDA $65M, net debt $190M. At 7.5x, EV $487M, equity $297M, stock $14.66.

Bear (30%): OEM doesn't recover, DC softer than expected, leverage exceeds covenant. EBITDA $45M, goodwill impairment probable, Wells Fargo controls the outcome. Stock approximately $6.

Probability-weighted target: $14.62 vs current $18.84. Implied return: -22.4%.

Forward alpha (Paleologo method): raw return minus risk-free (5%), multiplied by edge percentage (50% — DC corroboration is strong, leverage insight is real): alpha = -13.7% annualized.

No combination of realistic assumptions produces positive alpha at $18.84. I ran the sensitivity: alpha doesn't turn positive until the stock drops to $13-14 (where the CEO and CFO bought), OR Q1 de-risks the leverage gate AND the stock drops below $16. At current price, even cutting the bear probability to 15% and raising base EBITDA to $75M only gets you to breakeven.

The Paradox

There's a narrow window where this becomes interesting: Q1 earnings are bad enough to push the stock to $13-14 but not so bad that leverage exceeds 5.25x. That window might open. But you can't position for it in advance — buying here is paying for the recovery before it arrives.

May 5 earnings is the decision point. Q1 leverage below 4.0x and the stock below $15 opens the entry zone. Leverage above 5.0x and you walk away. The covenant schedule is unforgiving — it steps down to 5.00x in Q3, 4.00x in Q4, and back to 3.50x in 2027. MEC has to deleverage or die.

Verdict

The thesis is legitimate — DC misclassification with cross-ticker corroboration, 17.9% margins, growing secular demand. But at $18.84, the market has already priced the recovery. You're not buying the trough. You're buying the consensus EBITDA bridge from $47M to $85M, which requires everything to go right at once.

Watchlist only. The alpha lives at $13-14, not $18.84.

Evidence